{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 451553392
| IUPAC_name = (2''S'')-2-[(''S'')-(2-ethoxyphenoxy)phenyl<br />methyl]morpholine
| image = Esreboxetine.svg
| width = 150

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Uncontrolled
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 4808
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 98819-76-2
| ATC_prefix = None
| ATC_suffix =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = L8S50ZY490
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D09340
| PubChem = 65856
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 59268
| smiles = CCOC1=CC=CC=C1O[C@H]([C@@H]2CNCCO2)C3=CC=CC=C3
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C19H23NO3/c1-2-21-16-10-6-7-11-17(16)23-19(15-8-4-3-5-9-15)18-14-20-12-13-22-18/h3-11,18-20H,2,12-14H2,1H3/t18-,19-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = CBQGYUDMJHNJBX-OALUTQOASA-N

<!--Chemical data-->
| C=19 | H=23 | N=1 | O=3 
| molecular_weight = 313.391 g/mol
}}

'''Esreboxetine''' is a [[binding selectivity|selective]] [[norepinephrine reuptake inhibitor]] which was under development by [[Pfizer]] for the treatment of [[neuropathic pain]] and [[fibromyalgia]] but failed to show significant benefit over currently available medications and was discontinued.<ref name="isbn3-540-87911-0">{{cite book |author1=Matilda Bingham |author2=Napier, Susan Jolliffe | title = Transporters as Targets for Drugs (Topics in Medicinal Chemistry) | publisher = Springer | location = Berlin | year = 2009 | pages = | isbn = 3-540-87911-0 | oclc = | doi = | url = https://books.google.com/books?id=u5nVEyVchwUC&lpg=PA81&dq=esreboxetine&pg=PA81#v=onepage&q=&f=false}}</ref><ref name="pmid19732029">{{cite journal | author = Rao SG | title = Current progress in the pharmacological therapy of fibromyalgia | journal = Expert Opinion on Investigational Drugs | volume = 18 | issue = 10 | pages = 1479–93 |date=October 2009 | pmid = 19732029 | doi = 10.1517/13543780903203771 | url = http://informahealthcare.com/doi/abs/10.1517/13543780903203771}}</ref><ref name="urlSearch of: esreboxetine - List Results - ClinicalTrials.gov">{{cite web | url = http://clinicaltrials.gov/ct2/results?term=esreboxetine | title = Search of: esreboxetine - List Results - ClinicalTrials.gov | format = | work = | accessdate = }}</ref><ref name="urlMusculoskeletal Report: Pfizer Stops Work on Esreboxetine for FM">{{cite web | url = http://www.mskreport.com/articles.cfm?articleID=3293 | title = Musculoskeletal Report: Pfizer Stops Work on Esreboxetine for FM | format = | work = | accessdate = }}</ref> It is the (''S'',''S'')-(+)-[[enantiomer]] of [[reboxetine]] and is even more selective in comparison.<ref name="isbn3-540-87911-0"/><ref name="doi10.1016/j.tetlet.2008.11.025">{{Cite journal| doi = 10.1016/j.tetlet.2008.11.025| title = Enantioselective synthesis of (R)- and (S)-N-Boc-morpholine-2-carboxylic acids by enzyme-catalyzed kinetic resolution: application to the synthesis of reboxetine analogs | first15 = F.| last15 = Wakenhut | first14 = M.| last14 = Skerten | first13 = T.| last13 = Ryckmans | first12 = K.| last12 = Reeves| year = 2009 | first11 = B.| last1 = Fish| last11 = Patel | first1 = P. V.| last2 = MacKenny | first10 = C. | first2 = M.| last3 = Bish | first3 = G.| last4 = Buxton | first4 = T.| last10 = Pasquinet| last5 = Cave | first5 = R.| last6 = Drouard | first6 = D.| last7 = Hoople | first7 = D.| last8 = Jessiman | first8 = A.| last9 = Miller | first9 = D.| journal = Tetrahedron Letters| volume = 50| issue = 4| pages = 389 }}</ref>

However, recently it has been shown that esreboxetine could be effective in fibromyalgia patients.<ref>Arnold, L. M., Hirsch, I., Sanders, P., Ellis, A. and Hughes, B. (2012), Safety and efficacy of esreboxetine in patients with fibromyalgia: A fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis & Rheumatism, 64: 2387–2397. doi: 10.1002/art.34390</ref>

== See also ==
* [[Reboxetine]]

== References ==
{{Reflist|2}}

{{Stimulants}}
{{Analgesics}}
{{Monoamine reuptake inhibitors}}

[[Category:Enantiopure drugs]]
[[Category:Morpholines]]
[[Category:Norepinephrine reuptake inhibitors]]
[[Category:Phenol ethers]]

{{analgesic-stub}}